Ikena Oncology, Inc. (IKNA)

Ikena Oncology Statistics

Total Valuation

Ikena Oncology has a market cap or net worth of $77.70 million. The enterprise value is -$52.43 million.

Market Cap	77.70M
Enterprise Value	-52.43M

Important Dates

The last earnings date was Thursday, November 7, 2024, before market open.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 24.03% in one year.

Current Share Class	41.89M
Shares Outstanding	48.26M
Shares Change (YoY)	+24.03%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.52%
Owned by Institutions (%)	21.30%
Float	10.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	121.32
Forward PS	n/a
PB Ratio	0.60
P/TBV Ratio	0.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.32, with a Debt / Equity ratio of 0.06.

Current Ratio	15.32
Quick Ratio	14.94
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -37.08% and return on invested capital (ROIC) is -23.54%.

Return on Equity (ROE)	-37.08%
Return on Assets (ROA)	-22.06%
Return on Capital (ROIC)	-23.54%
Revenue Per Employee	$15,326
Profits Per Employee	-$1.39M
Employee Count	43
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-63,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -12.64% in the last 52 weeks. The beta is 0.50, so Ikena Oncology's price volatility has been lower than the market average.

Beta (5Y)	0.50
52-Week Price Change	-12.64%
50-Day Moving Average	1.68
200-Day Moving Average	1.61
Relative Strength Index (RSI)	45.37
Average Volume (20 Days)	445,419

Short Selling Information

The latest short interest is 78,105, so 0.16% of the outstanding shares have been sold short.

Short Interest	78,105
Short Previous Month	90,557
Short % of Shares Out	0.16%
Short % of Float	0.76%
Short Ratio (days to cover)	0.83

Income Statement

In the last 12 months, Ikena Oncology had revenue of $659,000 and -$59.60 million in losses. Loss per share was -$1.24.

Revenue	659,000
Gross Profit	-39.91M
Operating Income	-64.29M
Pretax Income	-66.78M
Net Income	-59.60M
EBITDA	-63.58M
EBIT	-64.29M
Loss Per Share	-$1.24

Balance Sheet

The company has $138.03 million in cash and $8.39 million in debt, giving a net cash position of $129.64 million or $2.69 per share.

Cash & Cash Equivalents	138.03M
Total Debt	8.39M
Net Cash	129.64M
Net Cash Per Share	$2.69
Equity (Book Value)	134.23M
Book Value Per Share	2.78
Working Capital	132.29M

Cash Flow

In the last 12 months, operating cash flow was -$61.56 million and capital expenditures -$262,000, giving a free cash flow of -$61.83 million.

Operating Cash Flow	-61.56M
Capital Expenditures	-262,000
Free Cash Flow	-61.83M
FCF Per Share	-$1.28

Margins

Gross Margin	n/a
Operating Margin	-9,755.24%
Pretax Margin	-9,053.41%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Ikena Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.03%
Shareholder Yield	-24.03%
Earnings Yield	-77.19%
FCF Yield	-80.07%

Analyst Forecast

The average price target for Ikena Oncology is $3.00, which is 86.34% higher than the current price. The consensus rating is "Buy".

Price Target	$3.00
Price Target Difference	86.34%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	36.47%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ikena Oncology has an Altman Z-Score of 0.17 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.17
Piotroski F-Score	1